Compare · NVO vs PTCT
NVO vs PTCT
Side-by-side comparison of Novo Nordisk A/S (NVO) and PTC Therapeutics Inc. (PTCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PTCT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 32.6x PTCT ($5.89B).
- Over the past year, NVO is down 43.1% and PTCT is up 37.2% - PTCT leads by 80.3 points.
- NVO has been more active in the news (7 items in the past 4 weeks vs 3 for PTCT).
- Both have 25 recent analyst ratings on file.
- Company
- Novo Nordisk A/S
- PTC Therapeutics Inc.
- Price
- $42.94-1.84%
- $70.94+0.51%
- Market cap
- $191.82B
- $5.89B
- 1M return
- -6.14%
- +6.56%
- 1Y return
- -43.10%
- +37.19%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 7
- 3
- Recent ratings
- 25
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
PTC Therapeutics Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Latest PTCT
- PTC Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- PTC Therapeutics upgraded by Jefferies with a new price target
- EXEC. VP AND CLO Boulding Mark Elliott sold $202,958 worth of shares (2,812 units at $72.18) as part of a pre-agreed trading plan and exercised 2,812 shares at a strike of $25.69 (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $917,154 worth of shares (12,572 units at $72.95) and was granted 12,500 shares, decreasing direct ownership by 0.02% to 393,998 units (SEC Form 4) to satisfy tax liability
- Amendment: SEC Form SCHEDULE 13G/A filed by PTC Therapeutics Inc.
- EXEC. VP AND CLO Boulding Mark Elliott exercised 3,540 shares at a strike of $46.54 and sold $279,570 worth of shares (3,540 units at $78.97) as part of a pre-agreed trading plan (SEC Form 4)
- PTC Therapeutics upgraded by TD Cowen with a new price target
- SEC Form 10-Q filed by PTC Therapeutics Inc.
- PTC Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results